Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313360132> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W4313360132 endingPage "204.12" @default.
- W4313360132 startingPage "204.12" @default.
- W4313360132 abstract "Abstract Cyclophosphamide (CTX) has been used as a lymphoablative conditioning agent to deplete regulatory T cells (Tregs) and enhance the efficacy of adoptive immune therapies. We initially investigated whether CTX conditioning could enhance the immunogenicity of melanoma Ag-pulsed dendritic cells (DC) in a murine model. CTX enhanced Ag-specific CD8+ T cell responses and control of SC-growing OVA+ melanoma following immunization with activated OVA257–265-pulsed DC; immunogenicity and tumor control were abrogated by reconstitution of Treg compartments. Unexpectedly, CTX-conditioned, DC-immunized animals developed significant vitiligo, despite the absence of exogenous melanocyte-specific Ag in the vaccine. CTX treatment or DC immunization alone failed to induce vitiligo. Injection of CTX-conditioned mice with MHC class II−/− DC, but not β2 microglobulin−/− DC, induced vitiligo regardless of exogenous Ag, suggesting that the induction of vitiligo may result from cross-presentation of endogenous melanocyte Ag in an environment of relaxed tolerance. Ab-mediated depletion of CD8 cells abrogated the vitiligo. These data suggest that CTX conditioning liberates class I-restricted melanocyte Ag for cross-presentation by activated DC to cognate CD8 cells, which in turn, achieve full activation and effector function in the absence of a normal regulatory environment. CTX conditioning may also open dermal compartments for increased effector T cell infiltration. Thus, CTX mediates multiple immunomodulatory mechanisms that may impact the future design of immunotherapy for melanoma." @default.
- W4313360132 created "2023-01-06" @default.
- W4313360132 creator A5030146567 @default.
- W4313360132 creator A5087654744 @default.
- W4313360132 date "2017-05-01" @default.
- W4313360132 modified "2023-09-26" @default.
- W4313360132 title "Cyclophosphamide preconditioning facilitates autoimmune vitiligo and enhanced antitumor efficacy following vaccination with activated dendritic cells." @default.
- W4313360132 doi "https://doi.org/10.4049/jimmunol.198.supp.204.12" @default.
- W4313360132 hasPublicationYear "2017" @default.
- W4313360132 type Work @default.
- W4313360132 citedByCount "0" @default.
- W4313360132 crossrefType "journal-article" @default.
- W4313360132 hasAuthorship W4313360132A5030146567 @default.
- W4313360132 hasAuthorship W4313360132A5087654744 @default.
- W4313360132 hasConcept C154317977 @default.
- W4313360132 hasConcept C167672396 @default.
- W4313360132 hasConcept C170627219 @default.
- W4313360132 hasConcept C202751555 @default.
- W4313360132 hasConcept C203014093 @default.
- W4313360132 hasConcept C2777658100 @default.
- W4313360132 hasConcept C2777701055 @default.
- W4313360132 hasConcept C2778170410 @default.
- W4313360132 hasConcept C2778973524 @default.
- W4313360132 hasConcept C2779727006 @default.
- W4313360132 hasConcept C2779980618 @default.
- W4313360132 hasConcept C2780868878 @default.
- W4313360132 hasConcept C502942594 @default.
- W4313360132 hasConcept C55493867 @default.
- W4313360132 hasConcept C71924100 @default.
- W4313360132 hasConcept C86803240 @default.
- W4313360132 hasConcept C8891405 @default.
- W4313360132 hasConceptScore W4313360132C154317977 @default.
- W4313360132 hasConceptScore W4313360132C167672396 @default.
- W4313360132 hasConceptScore W4313360132C170627219 @default.
- W4313360132 hasConceptScore W4313360132C202751555 @default.
- W4313360132 hasConceptScore W4313360132C203014093 @default.
- W4313360132 hasConceptScore W4313360132C2777658100 @default.
- W4313360132 hasConceptScore W4313360132C2777701055 @default.
- W4313360132 hasConceptScore W4313360132C2778170410 @default.
- W4313360132 hasConceptScore W4313360132C2778973524 @default.
- W4313360132 hasConceptScore W4313360132C2779727006 @default.
- W4313360132 hasConceptScore W4313360132C2779980618 @default.
- W4313360132 hasConceptScore W4313360132C2780868878 @default.
- W4313360132 hasConceptScore W4313360132C502942594 @default.
- W4313360132 hasConceptScore W4313360132C55493867 @default.
- W4313360132 hasConceptScore W4313360132C71924100 @default.
- W4313360132 hasConceptScore W4313360132C86803240 @default.
- W4313360132 hasConceptScore W4313360132C8891405 @default.
- W4313360132 hasIssue "1_Supplement" @default.
- W4313360132 hasLocation W43133601321 @default.
- W4313360132 hasOpenAccess W4313360132 @default.
- W4313360132 hasPrimaryLocation W43133601321 @default.
- W4313360132 hasRelatedWork W1492294511 @default.
- W4313360132 hasRelatedWork W1526433952 @default.
- W4313360132 hasRelatedWork W1565298727 @default.
- W4313360132 hasRelatedWork W1584203472 @default.
- W4313360132 hasRelatedWork W1987306912 @default.
- W4313360132 hasRelatedWork W2047225250 @default.
- W4313360132 hasRelatedWork W2063550875 @default.
- W4313360132 hasRelatedWork W2437929152 @default.
- W4313360132 hasRelatedWork W2821255169 @default.
- W4313360132 hasRelatedWork W3029773949 @default.
- W4313360132 hasVolume "198" @default.
- W4313360132 isParatext "false" @default.
- W4313360132 isRetracted "false" @default.
- W4313360132 workType "article" @default.